IntraCoronary Abciximab With the ClearWay Catheter To Improve Outcomes With Lysis

Trial Profile

IntraCoronary Abciximab With the ClearWay Catheter To Improve Outcomes With Lysis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2013

At a glance

  • Drugs Abciximab (Primary)
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms IC-CLEARLY
  • Most Recent Events

    • 01 Jun 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top